CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The CCTG Phase III Team Award for Intergroup-Led Trials was presented to the CO29 Team BCCA from Vancouver Cancer Centre and the Annual Spring Meeting. The team awards are presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance.
Dr. Courtney Coschi was recognized with the Elizabeth Eisenhauer Early Drug Development Young Investigator Award at the CCTG Spring Meeting. The award is presented to a new investigator who has worked at the CCTG Central Office, IND projects, or has contributed significantly to the conduct of an IND trial at a member centre.
Congrats to the MA39 clinical trials team at Tom Baker Cancer Centre in Calgary for receiving the ,Phase III Team Award for CCTG-Led Trials at a ceremony recently held at the Annual Spring Meeting in Toronto. The team awards are presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance
Congratulations to the PR19 Team from the Odette Cancer Centre at Sunnybrook for being recognized with the Phase III Team Award for CCTG-Led Trials.
CCTG is very pleased to present the Joseph Pater Founder’s Award for Excellence in Clinical Trials Research to Dr. Jolie Ringash, a radiation oncologist at the University of Toronto. The award is presented yearly at the Spring Meeting to a clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
CCTG former Directors joint statement regarding US requirements for identity proofing and multi-factor authentication
Congratulations to Dr. Ali Hosni Abdalaty from Princess Margaret Cancer Centre (UHN) for his Ralph Meyer Phase III Program Young Investigator Award received at the CCTG Spring Meeting.
